Research Progress of PD 1/PD L1 Inhibitors in the Treatment of
Urological Tumors
Lv Han,
Yang Meng,
Zhu Jianguo
Abstract:Immune checkpoint inhibitors (ICIs) offer significant advantages for the treatment of
urologic tumors, enhancing the immune function of anti-tumor T cells by inhibiting PD-1 and PDL1
binding. They have been shown to be well tolerated and remarkably effective in clinical practice,
offering hope to many patients who are not well treated with conventional drugs. Clinical
trials in recent years have shown that anti-PD-1 and PD-L1 antibodies have good efficacy and safety
in the treatment of urologic tumors. These a… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.